- Home
- PBA vs WST Comparison
PBA vs WST Comparison
Compare PBA & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBA
- WST
- Stock Information
- Founded
- PBA 1997
- WST 1923
- Country
- PBA Canada
- WST United States
- Employees
- PBA N/A
- WST N/A
- Industry
- PBA Oil & Gas Production
- WST Medical/Dental Instruments
- Sector
- PBA Energy
- WST Health Care
- Exchange
- PBA Nasdaq
- WST Nasdaq
- Market Cap
- PBA 21.8B
- WST 15.6B
- IPO Year
- PBA N/A
- WST N/A
- Fundamental
- Price
- PBA $37.22
- WST $222.00
- Analyst Decision
- PBA
- WST Buy
- Analyst Count
- PBA 0
- WST 7
- Target Price
- PBA N/A
- WST $331.67
- AVG Volume (30 Days)
- PBA 1.6M
- WST 696.4K
- Earning Date
- PBA 08-07-2025
- WST 07-24-2025
- Dividend Yield
- PBA 5.34%
- WST 0.38%
- EPS Growth
- PBA N/A
- WST N/A
- EPS
- PBA 2.13
- WST 6.37
- Revenue
- PBA $5,653,459,489.00
- WST $2,895,800,000.00
- Revenue This Year
- PBA $13.50
- WST $3.38
- Revenue Next Year
- PBA $0.62
- WST $5.85
- P/E Ratio
- PBA $17.48
- WST $34.87
- Revenue Growth
- PBA 29.95
- WST N/A
- 52 Week Low
- PBA $34.13
- WST $187.43
- 52 Week High
- PBA $43.44
- WST $352.33
- Technical
- Relative Strength Index (RSI)
- PBA 48.22
- WST 55.47
- Support Level
- PBA $36.96
- WST $215.67
- Resistance Level
- PBA $37.63
- WST $226.80
- Average True Range (ATR)
- PBA 0.75
- WST 5.26
- MACD
- PBA 0.01
- WST -0.05
- Stochastic Oscillator
- PBA 33.87
- WST 65.84
About PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its operations include transmission pipelines, oil and gas gathering, fractionation, storage, and natural gas liquid exports.
About WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.